Chongqing Zhifei Biological Products Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Chongqing Zhifei Biological Products wird ein jährliches Gewinn- und Umsatzwachstum von 45.1% bzw. 17.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 43.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.2% betragen.

Wichtige Informationen

45.1%

Wachstumsrate der Gewinne

43.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	43.4%
Wachstumsrate der Einnahmen	17.3%
Zukünftige Eigenkapitalrendite	19.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	01 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Sep 30

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Sep 03

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Aug 23

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Jul 26

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

May 21

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Apr 26

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Mar 26

Gewinn- und Umsatzwachstumsprognosen

SZSE:300122 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	50,147	9,311	11,072	10,243	9
12/31/2025	53,335	9,807	6,738	8,690	13
12/31/2024	32,201	3,312	1,986	13,525	2
9/30/2024	36,432	3,690	2,331	3,346	N/A
6/30/2024	46,731	6,044	5,500	6,512	N/A
3/31/2024	53,141	7,496	4,665	5,763	N/A
12/31/2023	52,918	8,070	7,862	8,996	N/A
9/30/2023	49,712	8,462	2,476	3,586	N/A
6/30/2023	44,356	8,070	4,357	5,546	N/A
3/31/2023	40,596	7,648	2,951	4,266	N/A
1/1/2023	38,264	7,539	536	1,989	N/A
9/30/2022	36,647	7,412	-360	1,175	N/A
6/30/2022	35,835	8,447	-1,151	596	N/A
3/31/2022	35,567	11,193	3,452	5,305	N/A
12/31/2021	30,652	10,209	6,575	8,508	N/A
9/30/2021	25,969	9,226	7,515	9,350	N/A
6/30/2021	21,368	7,287	8,050	9,627	N/A
3/31/2021	16,482	3,723	2,691	3,868	N/A
12/31/2020	15,190	3,301	2,670	3,497	N/A
9/30/2020	13,971	3,082	2,554	3,272	N/A
6/30/2020	12,542	2,724	1,038	1,604	N/A
3/31/2020	10,928	2,381	691	1,318	N/A
12/31/2019	10,587	2,366	794	1,367	N/A
9/30/2019	9,400	2,128	598	1,145	N/A
6/30/2019	8,195	1,916	247	764	N/A
3/31/2019	6,684	1,694	-422	82	N/A
12/31/2018	5,228	1,451	106	586	N/A
9/30/2018	4,068	1,234	-326	98	N/A
6/30/2018	2,969	943	N/A	170	N/A
3/31/2018	2,019	632	N/A	298	N/A
12/31/2017	1,343	432	N/A	204	N/A
9/30/2017	942	311	N/A	207	N/A
6/30/2017	707	192	N/A	126	N/A
3/31/2017	464	34	N/A	87	N/A
12/31/2016	446	33	N/A	90	N/A
9/30/2016	431	44	N/A	253	N/A
6/30/2016	512	101	N/A	207	N/A
3/31/2016	660	209	N/A	265	N/A
12/31/2015	713	197	N/A	223	N/A
9/30/2015	779	172	N/A	143	N/A
6/30/2015	805	160	N/A	165	N/A
3/31/2015	835	153	N/A	167	N/A
12/31/2014	801	148	N/A	161	N/A
9/30/2014	777	136	N/A	153	N/A
6/30/2014	735	124	N/A	179	N/A
3/31/2014	758	132	N/A	157	N/A
12/31/2013	780	130	N/A	222	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 300122Das prognostizierte Gewinnwachstum (45.1% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 300122Die Erträge des Unternehmens (45.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.3% pro Jahr).

Hohe Wachstumserträge: 300122Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 300122Die Einnahmen des Unternehmens (17.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 300122Die Einnahmen des Unternehmens (17.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 300122Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.2%).

Chongqing Zhifei Biological Products Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 23%

Consensus revenue estimates fall by 27%

Price target decreased by 22% to CN¥38.55

Price target decreased by 9.7% to CN¥49.16

Price target decreased by 8.3% to CN¥53.66

Consensus EPS estimates fall by 20%

Recent updates

Consensus revenue estimates fall by 23%

Investor sentiment deteriorates as stock falls 24%

Insufficient new directors

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 34%

Chongqing Zhifei Biological Products Co., Ltd. Approves Election of Zhang Xinrong as Independent Director

Consensus revenue estimates fall by 27%

Price target decreased by 22% to CN¥38.55

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Now 22% overvalued

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares, Payable on 08 August 2024

Price target decreased by 9.7% to CN¥49.16

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Price target decreased by 8.3% to CN¥53.66

Chongqing Zhifei Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

Consensus EPS estimates fall by 20%

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Price target decreased by 7.4% to CN¥65.91

Chongqing Zhifei Biological Products Co., Ltd., Annual General Meeting, Jun 18, 2024

Investor sentiment deteriorates as stock falls 15%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) announces an Equity Buyback for CNY 500 million worth of its shares.

Investor sentiment improves as stock rises 16%

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Price target decreased by 8.2% to CN¥67.08

Price target decreased by 7.7% to CN¥72.05

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 32%

EVE Energy Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 June 2023

Consensus revenue estimates increase by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Price target decreased to CN¥121

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022

Investor sentiment improved over the past week

Chongqing Zhifei Biological Products Co., Ltd. Approves Cash Dividend for the Year 2021

Consensus forecasts updated

Price target decreased to CN¥148

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥193

Consensus EPS estimates increase by 10%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥1.82 (vs CN¥0.61 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥2.85 (vs CN¥0.62 in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥219

Consensus revenue estimates increase to CN¥26.1b

First quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 1Q 2020)

Investor sentiment deteriorated over the past week

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day high: CN¥167

Market bids up stock over the past week

Price target lowered to CN¥201